New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide

Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers u...

Full description

Saved in:
Bibliographic Details
Published in:骨研究：英文 2014, Vol.2 (4), p.252-258
Main Author: Sakae Tanaka Taiji Adachi Tatsuhiko Kuroda Toshitaka Nakamura Masataka Shiraki Toshitsugu Sugimoto Yasuhiro Takeuchi Mitsuru Saito John P Bilezikian
Format: Article
Language:Chinese
Subjects:
仿真模型
患者
治疗方案
甲状旁腺激素
肽
重构表面
骨形成
骨质疏松症
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on residual old bone. An increase in bone formation and a subsequent decrease were observed in the preliminary simulation. For each fitted time point, the predicted value was compared to the absolute values of the bone formation a
ISSN:2095-4700